Clinical Trial

To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 20, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a double-blind, placebo-controlled, randomized study of 96 days total duration to assess the effect of JUV-161 on muscle disuse atrophy. This will be a multicenter study in New Zealand and will include up to 40 healthy volunteers aged between 40 to 65 years of age. Following the screening period, subjects will be randomized to receive either weekly subcutaneous (SC) injections of one of two doses of JUV-161 or matching placebo for a period of approximately 6 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-21
Trial Details
NCT Number NCT07397468
Lead Sponsor Juvena Therapeutics
Conditions Healthy Volunteers
Enrollment 36 participants
Start Date 2026-02-28
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20